Regulatory Focus™ > News Articles > 3 > Recon: Cigna to Buy Express Scripts for More Than $50B

Recon: Cigna to Buy Express Scripts for More Than $50B

Posted 08 March 2018 | By Ana Mulero 

Recon: Cigna to Buy Express Scripts for More Than $50B

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

In Focus: US In Focus: International Pharmaceuticals & Biotechnology
  • Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star (Endpoints News) (Reuters) (The Japan Times)
  • FDA Says No 180-Day Exclusivity Forfeiture for Generic LIALDA Based on Changed Bioequivalence Recommendations (FDA Law Blog)
  • UnitedHealthcare’s Point-of-Sale Rebate Announcement: What’s Next? (Drug Channels)
  • Challenges to Botox threaten a market makeover (Financial Times)
  • Lawmakers file a bill to block maneuvers like Allergan’s patent deal with Mohawks (Stat News-$)
  • Pharma to get another bite at the donut hole  (BioCentury)
  • Bye-bye, solo Express Scripts: What does the Cigna buyout mean for pharma? (Fierce)
  • Of ‘miracles’ and money: why hemophilia drugs are so expensive (Stat News)
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down (Endpoints News) (Fierce) (BioPharma Dive)
  • Merck KGaA's BTK drug hits in Phase 2 MS study (BioPharma Dive) (Fierce) (Press) (Reuters)
  • Getting clinical trials up and running is taking longer than ever (Stat News-$)
  • A CRISPR path to drug discovery (Nature)
  • Vinay Prasad on the NCCN’s cancer treatment guidelines: The US system needs an audit (BMJ)
  • It’s taking longer than before to get a drug trial underway, Tufts study concludes (Boston Globe)
  • Antiviral drug not beneficial for reducing mother-to-child transmission of hepatitis B when added to existing preventatives (NIH)
  • U.S. teens still denied morning-after pill (Reuters)
  • T2 Biosystems lands $2m grant for ‘superbug’ test (MassDevice)
  • InVivo wins FDA nod for new pivotal trial of its neuro-spinal scaffold (MassDevice)
  • Controversial study challenges scientific consensus that adult brains make new neurons (Stat News)
Medical Devices
  • Customizing the Sharing of Health Data (Medium)
  • Heart pump maker Abiomed settles U.S. kickback probe for $3.1m (Reuters) (MassDevice)
  • Philips and Samsung team up to expand the connected health ecosystem (Press)
  • Helix to grow DNA test ‘app store’ on first close of planned $200M series B (Fierce) (Stat News-$)
  • Panther Orthopedics wins FDA nod for Puma flexible fixation device (MassDevice) (Press)
  • Canon Medical acquires Dutch medtech dev Fysicon (MassDevice)
  • Calif. Court Restores Patient’s $4.5M Win In Hip Defect Suit (Law360-$)
  • A Brief Introduction to Medical Device Biocompatibility (MD+DI)
  • FMI Instrumed installs fifth metal Additive Manufacturing system for medical device production (Metal Additive Manufacturing magazine)
  • Premier Biotech’s Oral Fluid Drug Testing Device Granted FDA Clearance (Press)
US: Assorted & Government
  • How CMS plans to 're-examine' its relationship with insurers to drive patient-centric data sharing (Fierce) (Healthcare Informatics)
  • Survey Snapshot: Integrated Care Makes Sense — but Barriers Remain (NEJM)
  • Value-Based Transformation of America’s Healthcare System (HHS)
  • FDA did not issue new statement on vaccines and autism (Star Tribune)
  • CVS Prices $40B Bond Sale To Help Fund Aetna Acquisition (Law360-$)
  • Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments; Correction (FDA)
Upcoming Meetings & Events Europe Asia
  • Comprehensive and Progressive Agreement for Trans-Pacific Partnership May Differ Significantly from TPP (Patent Law Weblog)
  • Bi Jingquan, the Minister of CFDA Meets the Chief Executive of the Macao SAR, Mr Chui Sai On (CFDA)
  • JP drafts for public comments, March 1 - May 31, 2018 (PMDA)
  • Vectorious closes B round, setting stage for trials of heart-monitoring implant (Globes) (Fierce)
  • JW Therapeutics, a China CAR-T biotech formed by Juno and WuXi, gains $90M series A (Fierce)
India
  • NPPA analysis shows inflated MRP on syringes, needles (Times of India)
  • Dubai venture firm targets India’s health and education sectors (Arab News)
  • New Government Report Affirms India’s Patient-First Commitment on Pharma Patents (The Wire)
Australia
  • Fourth person dies in Australia from contaminated rockmelon (Asia One)
  • Alone at health clinic, Australian treats self for heart attack (Medical Xpress)
  • Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia (Press)
Canada
  • Why Some Canadian Doctors Are Trying to Get Paid Less, Not More (Fortune)
  • Seized health products in Vancouver may pose serious risks: Health Canada (News 1130)
  • Why do health-care ‘reforms’ always cut the patient stuff, not the wasteful stuff? (Financial Post)
  • Eyenuk, Inc. Receives Health Canada Approval for EyeArt, an AI-enabled Cloud-based Automated Diabetic Retinopathy Screening Software (Press)
  • Veritas Pharma Signs Letter of Intent with 3 Carbon Extractions Inc. (Press)
General Health & Other Interesting Articles
  • Drinking problems tied to higher risk of early dementia (Reuters)
  • A doctor without health insurance? What could go wrong? (Stat News)
Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.
 
Need to contact the editor of Regulatory Reconnaissance? Send us an email at news@raps.org.
 
A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or
RAPS.
 

Categories: Recon

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe